These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 22781608

  • 1. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 2. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M.
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [Abstract] [Full Text] [Related]

  • 3. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 4. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 5. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 6. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Mexican Hematology Study Group.
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [Abstract] [Full Text] [Related]

  • 7. [Efficacy of lower dose rituximab therapy for idiopathic thrombocytopenic purpura.].
    Sui T, Xue F, Zhao HF, Ge J, Zhou H, Zhang L, Bai J, Yang RC.
    Zhonghua Xue Ye Xue Za Zhi; 2010 Mar; 31(3):161-3. PubMed ID: 20510104
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 10. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H, Gruhn B, Werner U, Schorner U, Häfer R, Zintl F, Barz D.
    Acta Haematol; 2004 Sep; 111(4):221-4. PubMed ID: 15153715
    [Abstract] [Full Text] [Related]

  • 11. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 12. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 13. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B, Lindholm C, Pullerits R.
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [Abstract] [Full Text] [Related]

  • 14. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.
    Am J Ther; 2013 Jun; 20(2):219-22. PubMed ID: 23466621
    [Abstract] [Full Text] [Related]

  • 15. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z, Yang R.
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [Abstract] [Full Text] [Related]

  • 16. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P, Stipa E, La Presa M, Bianchi M, Di Giulio C, Stasi R, Amadori S.
    Recenti Prog Med; 2002 Jan; 93(7-8):421-7. PubMed ID: 12138687
    [Abstract] [Full Text] [Related]

  • 17. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 18. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS.
    Acta Haematol; 2006 Mar; 115(1-2):46-52. PubMed ID: 16424649
    [Abstract] [Full Text] [Related]

  • 20. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
    Lalayanni C, Stavroyianni N, Saloum R, Tsompanakou A, Anagnostopoulos A.
    Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.